Comparison of activated clotting times obtained using Hemochron and Medtronic analysers in patients receiving anti-thrombin therapy during cardiac catheterisation

Summary Accurate monitoring of anti-thrombin therapy with activated clotting time (ACT) is important to prevent thrombotic and haemorrhagic complications during cardiac catheterisation. Significant variability in ACT tests exists when different analysers are used. Our objective was to compare ACT results obtained using Hemochron→ and Medtronic ACT PLUS→ devices and anti-Xa activity in patients undergoing cardiac catheterisation. Thirty-two patients who received unfractionated heparin or argatroban therapy during cardiac catheterisation were enrolled. Blood sampling was performed to determine ACT values using Hemochron and Medtronic (with high-range cartridges) devices in all patients (n=130 pairs), and anti-Xa activity following heparin administration. In the heparin group, ACT tests (n=95 pairs) showed very good correlation (r=0.84, y=1.31x–0.81; p<0.001). However, Hemochron values were consistently higher and the difference more pronounced with increasing ACT (for ACT>150 sec, mean difference 65 ± 48 sec; p<0.001). Both Hemochron and Medtronic ACT tests correlated well with plasma anti-Xa levels (r=0.85, r=0.81, respectively; p<0.001); Hemochron ACT>300 sec corresponded to anti-Xa>1.48 IU/ml. With concomitant eptifibatide therapy, the divergence in ACT was greater compared to heparin alone. In the argatroban group, ACT tests (n=35 pairs) demonstrated excellent correlation (r=0.94, y=0.61x+79.9; p<0.001). In contrast to the heparin group, ACT values were higher with Medtronic compared to Hemochron. Therefore, despite good correlation between Hemochron and Medtronic ACT results, and strong association with anti-Xa activity, Medtronic ACT values were consistently lower compared to Hemochron following heparin anticoagulation. Paradoxically, Medtronic ACT results were higher after argatroban therapy. Understanding this discrepancy is crucial when using ACT to guide invasive cardiac procedures.

[1]  W. Chandler,et al.  Monitoring direct thrombin inhibitors with a plasma diluted thrombin time , 2007, Thrombosis and Haemostasis.

[2]  J. Ornato,et al.  ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update 2001 Guidelines for Percutaneous Coronary Intervention). , 2006, Circulation.

[3]  S. Spinler,et al.  Anticoagulation Monitoring Part 2: Unfractionated Heparin and Low-Molecular-Weight Heparin , 2005, The Annals of pharmacotherapy.

[4]  W. French,et al.  Reproducibility and variability of activated clotting time measurements in the cardiac catheterization laboratory , 2005, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[5]  Kadakia Ra,et al.  Optimal antithrombotic treatment for percutaneous coronary intervention. , 2005 .

[6]  S. Steinhubl,et al.  Relationship Between Activated Clotting Time and Ischemic or Hemorrhagic Complications: Analysis of 4 Recent Randomized Clinical Trials of Percutaneous Coronary Intervention , 2004, Circulation.

[7]  G. Dangas,et al.  Percutaneous interventions in patients with immune-mediated heparin-induced thrombocytopenia. , 2004, Seminars in thrombosis and hemostasis.

[8]  D. Sane,et al.  Direct thrombin inhibitors in the treatment of immune-mediated heparin-induced thrombocytopenia. , 2004, Seminars in thrombosis and hemostasis.

[9]  Deepak L. Bhatt,et al.  Revisiting optimal anticoagulation with unfractionated heparin during coronary stent implantation. , 2003, The American journal of cardiology.

[10]  J. Moses,et al.  Argatroban anticoagulation during percutaneous coronary intervention in patients with heparin‐induced thrombocytopenia , 2002, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[11]  J. Fareed,et al.  Monitoring of Argatroban in ARG310 Study: Potential Recommendations for its Use in Interventional Cardiology , 2002, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

[12]  H. Dauerman,et al.  Activated Clotting Times in the Setting of Eptifibatide Use During Percutaneous Coronary Intervention , 2002, Journal of Thrombosis and Thrombolysis.

[13]  Deepak L. Bhatt,et al.  Defining the Optimal Activated Clotting Time During Percutaneous Coronary Intervention: Aggregate Results From 6 Randomized, Controlled Trials , 2001, Circulation.

[14]  J. Ferguson.  Conventional antithrombotic approaches. , 1995, American heart journal.

[15]  R. Califf,et al.  Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of the Platelet Integrin Glycoprotein IIb/IIIa Blocker Integrelin in Elective Coronary Intervention , 1995 .

[16]  R. Califf,et al.  Effect of platelet glycoprotein IIb/IIIa integrin blockade on activated clotting time during percutaneous transluminal coronary angioplasty or directional atherectomy (the EPIC trial) , 1995 .

[17]  J. Ferguson,et al.  The use of activated clotting times to monitor heparin therapy during and after interventional procedures , 1994, Clinical cardiology.

[18]  J. Ferguson,et al.  Comparison of Hemochron and HemoTec activated coagulation time target values during percutaneous transluminal coronary angioplasty. , 1994, Journal of the American College of Cardiology.

[19]  D. Altman,et al.  STATISTICAL METHODS FOR ASSESSING AGREEMENT BETWEEN TWO METHODS OF CLINICAL MEASUREMENT , 1986, The Lancet.

[20]  B. Bull,et al.  Heparin therapy during extracorporeal circulation. II. The use of a dose-response curve to individualize heparin and protamine dosage. , 1975, The Journal of thoracic and cardiovascular surgery.

[21]  R. Yeh,et al.  Argatroban: update. , 2006, American heart journal.

[22]  J. Ferguson,et al.  Optimal antithrombotic treatment for percutaneous coronary intervention. , 2005, Minerva cardioangiologica.

[23]  S. Ellis,et al.  Multicenter, randomized, double-blind, placebo-controlled trial of the platelet integrin glycoprotein IIb/IIIa blocker Integrelin in elective coronary intervention. IMPACT Investigators. , 1995, Circulation.